Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05160129 · ClinicalTrials.gov registry record · NA

Connectomic Deep Brain Stimulation for Obsessive Compulsive Disorder

A NA study of Obsessive Compulsive Disorder (OCD), sponsored by Icahn School of Medicine at Mount Sinai.

Recruiting
Registry status
NA
Development phase
20
Enrollment target
1
Study location

NCT05160129 is a NA study of Obsessive Compulsive Disorder (OCD) that is actively recruiting participants, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 20 participants, below the 242-participant average among 12 other Obsessive Compulsive Disorder (OCD) trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05160129, a NA study of Obsessive Compulsive Disorder (OCD), is actively recruiting participants, sponsored by Icahn School of Medicine at Mount Sinai.

RECRUITING
Registry status
NA
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

Deep brain stimulation (DBS) is an effective treatment for people suffering from severe obsessive-compulsive disorder (OCD) whose symptoms have failed to improve after years and multiple methods of intervention. An effective DBS target for OCD is the anterior limb of the internal capsule (ALIC) brain region. On average 60% of all OCD patients have a clinically significant response to ALIC DBS. However, ALIC DBS may become even more effective with the ability to predict which specific ALIC connections in the brain need to be stimulated for each individual OCD patient. This study therefore investigates personalized stimulation to the ALIC that allows for precise modulation of brain circuits associated with individual OCD symptoms. The study aims to specify the ideal anatomical target for ALIC DBS for maximum therapeutic benefit in each patient.

Conditions Studied

Obsessive Compulsive Disorder (OCD)

Interventions

  • DEVICE Selective focal stimulation of ALIC-pathways

Study Locations (1)

New York

  • Mount Sinai West - New York

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2021-08-13
Est. Completion 2026-03-31
Phase NA

Sponsor

Icahn School of Medicine at Mount Sinai

708 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05160129

The ClinicalTrials.gov registry entry for NCT05160129 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 242-participant average among 12 other Obsessive Compulsive Disorder (OCD) trials with a reported enrollment target (92% lower). The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Obsessive Compulsive Disorder (OCD) appearing as the primary indexed condition, and to 1 intervention - of which Selective focal stimulation of ALIC-pathways is the first listed.

NCT05160129 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT05160129 about?

NCT05160129 is a clinical study titled "Connectomic Deep Brain Stimulation for Obsessive Compulsive Disorder". Deep brain stimulation (DBS) is an effective treatment for people suffering from severe obsessive-compulsive disorder (OCD) whose symptoms have failed to improve after years and multiple methods of intervention. An effective DBS target for OCD is the anterior limb of the internal capsule (ALIC) brai...

What is the current status of trial NCT05160129?

This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2021-08-13. Estimated completion is 2026-03-31.

What conditions does trial NCT05160129 study?

This clinical trial studies the following conditions: Obsessive Compulsive Disorder (OCD).

What interventions are being tested in trial NCT05160129?

The interventions under investigation include: Selective focal stimulation of ALIC-pathways (DEVICE).

Who is sponsoring clinical trial NCT05160129?

This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05160129 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Obsessive Compulsive Disorder (OCD)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Obsessive Compulsive Disorder (OCD)

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.